Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aumolertinib postoperative adjuvant therapy in EGFR-mutant stage IB and pure solid stage IA2-3 NSCLC
ChiCTR2200062887Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of almonertinib in non-small cell lung cancer (NSCLC) and Non-small cell lung cancer adenocarcinoma (NSCLC), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoint: 3-year disease-free survival. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
almonertinib
03
Conditions
non-small cell lung cancer (NSCLC)Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on ChiCTR2200062887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062887.